TVM Capital Healthcare Partners

Egg Medical, Inc. is a medical device company based in Arden Hills, Minnesota, established in 2014. The company specializes in manufacturing healthcare equipment, with its flagship product being EGGNEST, a cath lab patient table designed to significantly reduce scatter radiation exposure for both patients and medical staff during procedures requiring real-time imaging. EGGNEST features a carbon fiber sled base which enhances safety without interrupting the workflow in cath labs. This innovative system also incorporates an integrated antimicrobial feature, providing additional protection for physicians, surgeons, nurses, and technicians. By prioritizing safety and efficiency, Egg Medical enables healthcare professionals to conduct critical diagnostic and therapeutic procedures effectively.

Neurocare group provides mental health and performance by personalizing therapy following a detailed assessment.

DEBx Medical is a pioneering medical technology company focused on advanced wound care solutions aimed at improving the quality of life for individuals with chronic wounds. The company specializes in addressing the challenges associated with hard-to-heal wounds, particularly in infection management and biofilm removal. DEBx Medical provides a comprehensive approach that encompasses diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By offering innovative and effective solutions, the company enables healthcare providers to enhance patient outcomes while delivering affordable and user-friendly treatments that can be easily integrated into everyday clinical practice.

At Boston Oncology, we support the healthcare of citizens in emerging markets around the world through regional development and production of licensed biopharmaceutical products.

Neurocare group provides mental health and performance by personalizing therapy following a detailed assessment.

Smart Reporting GmbH is a Munich-based company that specializes in providing an online platform for structured medical reporting, primarily targeting radiology and pathology. Founded in 2014, the company offers an intelligent software solution that aids physicians in generating high-quality medical reports. The platform features automatic text suggestions, medically accurate terminology, and targeted illustrations, ensuring reports meet established guidelines. Additionally, Smart Reporting assists hospitals and medical practices in implementing report quality standards, optimizing report templates, and integrating with existing systems. The company also provides advanced statistical tools for quality assurance, multilingual reporting, and customizable templates. Furthermore, it offers solutions for medical registries and clinical studies, enabling simultaneous report generation and data submission while facilitating systematic quality assurance. Overall, Smart Reporting enhances the efficiency and quality of medical reporting, ultimately improving communication within healthcare settings.

Vektor Medical, based in San Diego, focuses on transforming arrhythmia care for individuals suffering from atrial fibrillation and other related conditions. The company has developed an advanced, non-invasive technology called vMap, which utilizes artificial intelligence for the analysis and mapping of cardiac arrhythmias. This solution employs computational modeling alongside the patient's electrocardiogram to accurately identify sources of arrhythmias, including both focal and fibrillation types. Vektor Medical's FDA-cleared technology enhances the efficiency of cardiac ablation procedures, optimizes clinical workflows, and ultimately aims to improve patient outcomes in arrhythmia management.

Myo is a communication platform specifically developed for the elderly care market. It facilitates connections between elderly individuals and their families, enhancing communication through familiar messaging features. The platform allows caregivers to share various forms of content, including photos, videos, texts, and voice messages, ensuring that interactions are professional, secure, and direct. Myo aims to improve the overall care experience by fostering meaningful connections among caregivers, elderly individuals, and their relatives. The company is also focused on expanding its team with talented individuals dedicated to enhancing care solutions.

DEBx Medical is a pioneering medical technology company focused on advanced wound care solutions aimed at improving the quality of life for individuals with chronic wounds. The company specializes in addressing the challenges associated with hard-to-heal wounds, particularly in infection management and biofilm removal. DEBx Medical provides a comprehensive approach that encompasses diagnosis, treatment, follow-up care, and maintenance of healthy wound beds. By offering innovative and effective solutions, the company enables healthcare providers to enhance patient outcomes while delivering affordable and user-friendly treatments that can be easily integrated into everyday clinical practice.

Recurv Pharma's RP-001 is a novel chemical entity (NCE) that is administered in a nano-emulsion formulation, concentrating medication delivery to the tumour while preserving healthy organs. Strong efficacy in a variety of pre-clinical tumour models, including non-small cell lung, breast, ovarian, prostate, pancreatic, and colorectal cancers, has allowed the chemical to show that it can destroy tumours even in multi-drug resistant tumours.

AMILI focuses on advancing gut microbiome research to address critical healthcare needs through the development of diagnostic tests, predictive algorithms, and microbiome-modifying interventions. The company collects gut microbiome stool samples to enhance its research and treatment capabilities, which aim to improve the health outcomes of patients suffering from infections and various diseases. Additionally, AMILI offers probiotics and conducts faecal microbiota transplants to support the treatment of bacterial infections. By utilizing its proprietary microbiome database, AMILI seeks to identify different types of gut microbiota, enabling medical professionals to leverage microbe science for better health management.

Egg Medical, Inc. is a medical device company based in Arden Hills, Minnesota, established in 2014. The company specializes in manufacturing healthcare equipment, with its flagship product being EGGNEST, a cath lab patient table designed to significantly reduce scatter radiation exposure for both patients and medical staff during procedures requiring real-time imaging. EGGNEST features a carbon fiber sled base which enhances safety without interrupting the workflow in cath labs. This innovative system also incorporates an integrated antimicrobial feature, providing additional protection for physicians, surgeons, nurses, and technicians. By prioritizing safety and efficiency, Egg Medical enables healthcare professionals to conduct critical diagnostic and therapeutic procedures effectively.

Centogene is a prominent genetic biotechnology company headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts. As a leader in genetic diagnostic analyses, Centogene specializes in addressing rare inherited diseases by transforming clinical, genetic, and biochemical data into actionable medical solutions. The company operates in two main segments: diagnostics and pharmaceuticals. Its diagnostics segment offers targeted genetic sequencing and diagnostic services to patients, while the pharmaceutical segment collaborates with partners to provide services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. Centogene is committed to enhancing awareness and support for patients of all ethnicities worldwide, consistently advancing research and developing innovative products in the field of human genetics.

Access Vascular, Inc., founded in 2015 and based in Bedford, Massachusetts, specializes in the development of venous access devices that utilize innovative hydrogel materials to prevent thrombosis, infections, and other complications associated with intravenous therapy. The company’s portfolio includes a range of products such as peripherally inserted central catheters, hemodialysis devices, implantable ports, and drug delivery systems. Access Vascular's technology aims to enhance clinical outcomes while reducing healthcare costs by minimizing the risk of blood clots and associated complications. Their flagship product, the HydroPICC, is designed to outperform existing technologies, potentially leading to shorter hospital stays and improved patient experiences. By addressing common challenges in venous access, Access Vascular seeks to improve the effectiveness and safety of intravenous treatments.

Kent Imaging Inc. is a medical device company based in Calgary, Canada, founded in 2006. It specializes in developing and commercializing multispectral oxygenation imaging technology aimed at improving patient outcomes in various medical fields, including plastic surgery, trauma, wound care, and cardiac specialties. The company's innovative imaging systems serve as a non-invasive tool for physicians, allowing them to assess tissue oxygen saturation without the need for contact or injected dyes. Kent Imaging is committed to enhancing healthcare solutions and holds multiple patents in medical technology. In addition to its headquarters in Calgary, the company has locations in Chicago, Los Angeles, Salt Lake City, and Seattle.

Vespina Lifesciences plans to develop to proof-of-concept a potential compound with the potential to treat certain types of inflammatory diseases including pulmonary indications with poor therapeutic options as well as non-pulmonary inflammatory diseases. The compound was originally discovered and characterized at Denmark-based Neuprozyme Therapeutics ApS. There are upwards of 70,000 patients newly diagnosed with bronchiectasis in the US every year as more than half of the 16+ million patients diagnosed with COPD in the US likely also have concurrent bronchiectasis. There are no approved treatments that specifically address the underlying mechanism of disease.

ImmunoRx Pharma develops an anti-body that treats certain types of chronic inflammatory diseases including ulcerative colitis, rheumatoid arthritis, and Crohn’s disease. The company's antibody targets a new critical target in chronic inflammation and auto-immunity which was originally discovered by Dr. Tessier in Canada.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Emovi specializes in advanced knee joint assessment technologies aimed at improving patient quality of life. The company has developed a device that serves as a diagnostic aid for knee injuries and osteoarthritis, providing medical professionals with actionable data on joint movement while weight-bearing. This technology helps in reducing pain, minimizing opioid use, and shortening recovery times for patients. Emovi's commitment to innovation in healthcare is reflected in its focus on delivering high-quality products that enhance the treatment and management of knee conditions.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Headquartered in Newton, Massachusetts, the company focuses on several clinical-stage candidates, including EDSIVO, aimed at treating vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, and ACER-001, a formulation of sodium phenylbutyrate for various inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing emetine hydrochloride as a potential treatment for COVID-19 and has a clinical-stage candidate, osanetant, for induced vasomotor symptoms. Founded in 2013, Acer Therapeutics is committed to addressing critical health challenges through innovative therapies.

Panthera Dental Inc., founded in 2011 by brothers Gabriel and Bernard Robichaud, specializes in the design, development, manufacturing, and marketing of dental restoration solutions and dental sleep appliances. Based in Québec, Canada, with an additional office in New Jersey, the company offers a variety of products, including Angulated Screw Channels, Metal Implant Bars, and the Diamart two-part implant bridge, which enhances rigidity and supports cantilevers. Other notable products include the Integrated Bar for easy cleaning, the Lock 'n' Release Bar designed for patients with dexterity issues, and the D-SAD dental appliance for snoring treatment. Panthera Dental aims to improve patient quality of life through innovative and personalized implant systems and has established itself as a leader in the prosthetic implant market.

Centogene is a prominent genetic biotechnology company headquartered in Rostock, Germany, with additional operations in Berlin and Cambridge, Massachusetts. As a leader in genetic diagnostic analyses, Centogene specializes in addressing rare inherited diseases by transforming clinical, genetic, and biochemical data into actionable medical solutions. The company operates in two main segments: diagnostics and pharmaceuticals. Its diagnostics segment offers targeted genetic sequencing and diagnostic services to patients, while the pharmaceutical segment collaborates with partners to provide services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. Centogene is committed to enhancing awareness and support for patients of all ethnicities worldwide, consistently advancing research and developing innovative products in the field of human genetics.

AL-S Pharma AG develops AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of ALS.

AurKa Pharma is a biopharmaceutical company focused on developing a single compound aimed at treating solid tumors. The company has completed GLP toxicology studies and plans to initiate clinical development, pending regulatory approval. The primary objective is to demonstrate clinical proof-of-concept of efficacy in solid tumors, with the potential to explore additional cancer indications in the future. Through this targeted approach, AurKa Pharma aims to enhance treatment options for patients suffering from cancer.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Headquartered in Newton, Massachusetts, the company focuses on several clinical-stage candidates, including EDSIVO, aimed at treating vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation, and ACER-001, a formulation of sodium phenylbutyrate for various inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing emetine hydrochloride as a potential treatment for COVID-19 and has a clinical-stage candidate, osanetant, for induced vasomotor symptoms. Founded in 2013, Acer Therapeutics is committed to addressing critical health challenges through innovative therapies.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through nanotechnology. The company develops a pipeline of next-generation nano-formulated drugs that improve the bioavailability of poorly water-soluble medications. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates either polymeric or crystalline nanoparticles designed to offer significant differentiation and added benefits for patients. In addition to its drug development efforts, the company provides services that support pre-clinical and clinical stage formulations for clients, including new chemical entities and established branded drugs. Through its innovative approach, Leon Nanodrugs aims to improve patient outcomes in the pharmaceutical industry.

Esperas Pharma is a special purpose company created to develop one compound to proof-of-concept.

CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina.

Manzil Health Care Services delivers healthcare services at the doorstep. Their services include physiotherapy, mother and baby care, lactation consultation, elder care, baby sitter services, caregiver services, ventilation at home, doctor at home, wound care, pediatric care, post-operation care, and more.

Amecath operates as a manufacturer and global distributor of medical products. It offers value catheters spanning across Urology, Venous Access, and Dialysis.

Cambridge Medical and Rehabilitation Center is a provider of post-acute care and rehabilitation services in the MENA region, focusing on patients with serious injuries or illnesses. The center aims to restore hope and ensure a continuum of care for both patients and their families. Utilizing modern technology alongside the expertise of physicians, physiotherapists, and speech and language pathologists, Cambridge Medical offers individualized treatment plans. Their range of services includes physical therapy, occupational therapy, speech-language therapy, hydrotherapy, and respiratory therapy. This comprehensive approach helps individuals with neurological issues to improve their health and achieve a level of independence, whether returning home on their own or with family support and home health services.

Bourn Hall is a fertility clinic based in Cambridge, United Kingdom, that offers in vitro fertilization (IVF) and related fertility treatments to both self-funding and NHS patients. Established by IVF pioneers Steptoe and Edwards, Bourn Hall made history as the first clinic in the world to provide IVF services. The clinic operates additional locations in Colchester, Norwich, and Wickford, often described as a sanctuary for individuals facing challenges in conceiving. Bourn Hall is dedicated to creating a safe and supportive environment for patients, addressing fertility-related issues for both men and women, and has successfully assisted in the conception of over 13,000 children.

ProVita is based on the groundbreaking and patient-centric work of founder Christina Shawky-Boehme, who first established Pro Vita Germany in 1995. Together the team at ProVita International Medical Center, Abu Dhabi, succeeded in creating an international care model and first facility of its kind in the UAE. With strong global ties and international nursing standards we are proud to offer a truly multicultural environment for our residens with around 300 internationally trained staff specializing in ICU and acute patient care as well as rehabilitation.